Moleculin Gross Profit from 2010 to 2025

MBRX Stock

USD 1.06 0.03 2.75%

Moleculin Biotech Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit will likely drop to about -120 K in 2025. Gross Profit is the profit Moleculin Biotech makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2015-12-31

Previous Quarter

-32 K

Current Value

-31 K

Quarterly Volatility

86.8 K

Yuan Drop

Covid

Check Moleculin Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moleculin Biotech's main balance sheet or income statement drivers, such as Interest Income of 965.1 K, Depreciation And Amortization of 245.5 K or Interest Expense of 2.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.03. Moleculin financial statements analysis is a perfect complement when working with Moleculin Biotech Valuation or Volatility modules.

Check out the analysis of Moleculin Biotech Correlation against competitors.

For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.

Latest Moleculin Biotech's Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Moleculin Biotech over the last few years. Gross profit is a required income statement account that reflects total revenue of Moleculin Biotech minus its cost of goods sold. It is profit before Moleculin Biotech operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Moleculin Biotech's Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moleculin Biotech's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Moleculin Gross Profit Regression Statistics

	Arithmetic Mean	(87,842)
	Geometric Mean	0.00
	Coefficient Of Variation	(116.64)
	Mean Deviation	87,302
	Median	(18,000)
	Standard Deviation	102,455
	Sample Variance	10.5B
	Range	285K
	R-Value	(0.72)
	Mean Square Error	5.4B
	R-Squared	0.52
	Significance	0
	Slope	(15,460)
	Total Sum of Squares	157.5B

Moleculin Gross Profit History

	2025	-120 K
	2024	-114.3 K
	2023	-127 K
	2022	-222 K
	2021	-260 K
	2020	-285 K
	2019	-185 K

Other Fundumenentals of Moleculin Biotech

Gross Profit Margin

Moleculin Biotech Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Capital Surpluse	Intangible Assets	Property Plant Equipment	Net Invested Capital	Net Working Capital	Net Receivables	Capital Stock
Total Assets		0.95	0.71	0.7	-0.95	-0.59	0.66	0.5	-0.69	0.95	-0.74	0.48	0.76	0.04	0.64	0.88	0.91	-0.11	0.13
Total Stockholder Equity	0.95		0.54	0.52	-0.99	-0.38	0.51	0.31	-0.56	0.99	-0.59	0.45	0.63	-0.16	0.48	0.88	0.89	-0.26	0.03
Net Tangible Assets	0.71	0.54		0.67	-0.57	-0.94	0.75	0.59	-0.6	0.57	-0.7	0.0	0.77	0.62	0.55	0.72	0.75	0.52	-0.13
Current Deferred Revenue	0.7	0.52	0.67		-0.49	-0.77	0.86	0.81	-0.85	0.51	-0.79	0.54	0.85	0.4	0.85	0.43	0.51	0.1	0.33
Net Debt	-0.95	-0.99	-0.57	-0.49		0.39	-0.49	-0.31	0.48	-1.0	0.58	-0.43	-0.64	0.15	-0.48	-0.91	-0.93	0.24	-0.04
Retained Earnings	-0.59	-0.38	-0.94	-0.77	0.39		-0.84	-0.79	0.68	-0.41	0.78	-0.15	-0.84	-0.7	-0.71	-0.51	-0.57	-0.5	-0.1
Accounts Payable	0.66	0.51	0.75	0.86	-0.49	-0.84		0.88	-0.79	0.52	-0.88	0.48	0.88	0.37	0.84	0.41	0.5	0.14	0.23
Total Liab	0.5	0.31	0.59	0.81	-0.31	-0.79	0.88		-0.75	0.34	-0.87	0.63	0.88	0.42	0.91	0.2	0.32	0.11	0.57
Short Long Term Debt	-0.69	-0.56	-0.6	-0.85	0.48	0.68	-0.79	-0.75		-0.49	0.81	-0.52	-0.77	-0.35	-0.76	-0.38	-0.45	-0.07	-0.29
Total Current Assets	0.95	0.99	0.57	0.51	-1.0	-0.41	0.52	0.34	-0.49		-0.61	0.45	0.66	-0.15	0.5	0.9	0.92	-0.25	0.07
Short Term Debt	-0.74	-0.59	-0.7	-0.79	0.58	0.78	-0.88	-0.87	0.81	-0.61		-0.58	-0.9	-0.35	-0.94	-0.51	-0.6	-0.01	-0.4
Common Stock	0.48	0.45	0.0	0.54	-0.43	-0.15	0.48	0.63	-0.52	0.45	-0.58		0.56	-0.34	0.72	0.1	0.2	-0.64	0.83
Capital Surpluse	0.76	0.63	0.77	0.85	-0.64	-0.84	0.88	0.88	-0.77	0.66	-0.9	0.56		0.41	0.89	0.59	0.67	0.04	0.39
Intangible Assets	0.04	-0.16	0.62	0.4	0.15	-0.7	0.37	0.42	-0.35	-0.15	-0.35	-0.34	0.41		0.31	0.14	0.17	0.7	-0.1
Property Plant Equipment	0.64	0.48	0.55	0.85	-0.48	-0.71	0.84	0.91	-0.76	0.5	-0.94	0.72	0.89	0.31		0.37	0.48	-0.12	0.6
Net Invested Capital	0.88	0.88	0.72	0.43	-0.91	-0.51	0.41	0.2	-0.38	0.9	-0.51	0.1	0.59	0.14	0.37		0.99	0.03	-0.16
Net Working Capital	0.91	0.89	0.75	0.51	-0.93	-0.57	0.5	0.32	-0.45	0.92	-0.6	0.2	0.67	0.17	0.48	0.99		0.01	-0.05
Net Receivables	-0.11	-0.26	0.52	0.1	0.24	-0.5	0.14	0.11	-0.07	-0.25	-0.01	-0.64	0.04	0.7	-0.12	0.03	0.01		-0.53
Capital Stock	0.13	0.03	-0.13	0.33	-0.04	-0.1	0.23	0.57	-0.29	0.07	-0.4	0.83	0.39	-0.1	0.6	-0.16	-0.05	-0.53

Click cells to compare fundamentals

About Moleculin Biotech Financial Statements

Moleculin Biotech investors use historical fundamental indicators, such as Moleculin Biotech's Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Moleculin Biotech. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Gross Profit	-114.3 K	-120 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Moleculin Stock Analysis

When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC